Oncology

As survival rates for malignant melanoma increase, so does the likelihood that some patients will develop second primary cancers.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Weeks after the first 2 anticancer biosimilars entered the US market, OneOncology announced that its partner practices have already started administering the drugs.

Innovation is being used to improve quality metrics in oncology care at the patient forefront and in data, explained Lani M. Alison, BSN, MS, HCQ, PCMH, CCE, vice president of Clinical Affairs, Regional Cancer Care Associates.

A single-dose human papillomavirus (HPV) vaccination strategy could be effective in less developed countries, where cost is in consideration.

High costs of care, particularly for prescription drugs, dominated a discussion of cancer care at the state level during the June 27, 2019, National Comprehensive Cancer Network Policy Summit in Washington, DC.

The study found that the advantage was due to factors that affect hospital safety, which were present before affiliation and increased afterward.

Nivolumab (Opdivo) monotherapy is currently indicated for the treatment of patients with hepatocellular carcinoma who were previously treated with the targeted therapy sorafenib, sold as Nexavar, based on the CheckMate 040 trial. Assessing the safety and efficacy of nivolumab in combination with ipilimumab (Yervoy) among these patients, researchers have observed clinically meaningful responses and an acceptable safety profile.

Researchers from Houston Methodist Cancer Center and The University of Texas MD Anderson Cancer Center said they demonstrated a new monoclonal antibody blocked ovarian and pancreatic tumor activity in mice.

When it comes to performing high-risk procedures, the majority of hospitals do not perform them often enough to meet safety standards, according to a new report from The Leapfrog Group.

A phase 2b clinical trial is producing promising results for a personalized cancer vaccine used in patients with stage III and IV resected melanoma.

Financial toxicity, ACO contracts, removing barriers to care.

Selected abstracts from the 2019 Annual Meeting of the American Society of Clinical Oncology.

Research on biosimilars presented at the 2019 Annual Meeting of the American Society of Clinical Oncology.

From the Oncology Care Model to the possibilities of cannabis, policy issues drew big crowds at the 2019 Annual Meeting of the American Society of Clinical Oncology.

Cytokine release syndrome represents a major concern, and source of costs, associated with the life-saving gene therapy.

Real-world evidence is being embraced by FDA as a way to expand the review of data beyond the trial population, which may not be representative of the patients seen in clinics on a daily basis.

Clinical findings presented at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) demonstrated significant clinical benefit in patients with solid pediatric tumors that progressed in adulthood, a patient population with few treatment options, according to study findings presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.

Although smoking cigarettes is thought of as being the most prevalent—yet preventable—cancer risk, new data suggests people who are obese now outnumber people who smoke, with excess weight causing more cases of certain cancers than smoking in the United Kingdom.

CMS has proposed the mandatory Radiation Oncology Model, which would cover radiation therapy spanning a 90-day episode.

Poor interpretation of imaging is the top reason for oncology malpractice lawsuits.

Time to diagnosis, the interval that passes from first symptom presentation until diagnosis, varies by cancer type among children, adolescents, and young adults and may be affected by clinical and sociodemogrpahic factors.

New innovations in cancer therapies have people excited to leave behind the treatments of old, but it might not be time yet to throw away chemotherapy, said Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions.